Shares rise 5.4% following groundbreaking approval of once-daily prophylactic injection for hemophilia A and B with inhibitors.
Share this post
📰 FDA Approves Novo Nordisk’s Alhemo for…
Share this post
Shares rise 5.4% following groundbreaking approval of once-daily prophylactic injection for hemophilia A and B with inhibitors.